论文部分内容阅读
目的探讨不同化疗方案对乳腺癌合并糖尿病患者的血糖影响及相关调控处理策略。方法回顾性分析33例乳腺癌合并糖尿病患者在接受化疗期间的血糖监控情况及相应的处理措施。结果有6、13、14例患者分别接受CAF(5-氟尿嘧啶、多柔比星、环磷酰胺)方案、TThp(吡柔比星联合多西他赛)或AT(多柔比星联合紫杉醇)方案化疗,所有患者均顺利完成化疗周期,化疗期间CAF、TThp及AT方案分别有2、3、3例患者出现血糖异常升高,需增加胰岛素用量,未出现尿酮体、酮症酸中毒等严重的不良反应。结论不同化疗方案均可引起血糖代谢异常,密切监视血糖动态变化,合理地使用降糖药物可以确保化疗安全进行。
Objective To investigate the effect of different chemotherapy regimens on the blood glucose in patients with breast cancer complicated with diabetes mellitus and the related control strategy. Methods A retrospective analysis of 33 cases of breast cancer with diabetes mellitus during the treatment of blood glucose monitoring and the corresponding treatment measures. RESULTS: 6,13,14 patients underwent CAF (fluorouracil, doxorubicin, cyclophosphamide) regimens, TThp (pirarubicin plus docetaxel), or AT (doxorubicin plus paclitaxel) Chemotherapy, all patients were successfully completed the cycle of chemotherapy, chemotherapy regimen CAF, TThp and AT programs were 2,3,3 cases of patients with abnormal blood glucose, need to increase insulin dosage, no ketone body, ketoacidosis and other serious Adverse reactions. Conclusion Different chemotherapy regimens can cause abnormal blood glucose metabolism and closely monitor the dynamic changes of blood glucose. The rational use of hypoglycemic drugs can ensure the safety of chemotherapy.